These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
141 related articles for article (PubMed ID: 3512825)
1. Development of new drugs in man: a review. Davies IB; Grind IM; Pottage A; Turner P J R Soc Med; 1986 Feb; 79(2):96-9. PubMed ID: 3512825 [No Abstract] [Full Text] [Related]
2. Are the drug-regulatory agencies paper villains? Smith T Br Med J; 1980 Nov; 281(6251):1333-5. PubMed ID: 7002251 [No Abstract] [Full Text] [Related]
3. Clinical trials of drugs from the viewpoint of the pharmaceutical industry. Peltier HC Clin Pharmacol Ther; 1975 Nov; 18(5 Pt 2):637-42. PubMed ID: 1102239 [No Abstract] [Full Text] [Related]
4. Drug famine: possible solutions. Smith T Br Med J; 1980 Nov; 281(6253):1475-7. PubMed ID: 7437842 [No Abstract] [Full Text] [Related]
5. Drug development: risks and problems. Azarnoff DL; Herting RL Ann N Y Acad Sci; 1984; 432():279-85. PubMed ID: 6395765 [No Abstract] [Full Text] [Related]
6. Minimum acceptable requirements for introduction and marketing of drugs. Lasagna L Drugs; 1974; 7(6):409-13. PubMed ID: 4422210 [No Abstract] [Full Text] [Related]
7. The drug approval process and the FDA. Schmidt AM Conn Med; 1975 Apr; 39(4):237-40. PubMed ID: 1149447 [No Abstract] [Full Text] [Related]
8. Promoting, improving and accelerating the drug development and approval processes. Graul AI Drug News Perspect; 2007; 20(1):45-55. PubMed ID: 17332899 [TBL] [Abstract][Full Text] [Related]
9. Getting the Dose Right: report from the Tenth European Federation of Pharmaceutical Sciences (EUFEPS) conference on optimizing drug development. Stanski DR; Rowland M; Sheiner LB J Pharmacokinet Pharmacodyn; 2005 Apr; 32(2):199-211. PubMed ID: 16283539 [TBL] [Abstract][Full Text] [Related]
10. [Administrative and juridicial problems in psychopharmacology (author's transl)]. Heimann H Arzneimittelforschung; 1975 Nov; 25(11):1809-13. PubMed ID: 1106443 [TBL] [Abstract][Full Text] [Related]
11. Washington Report. Drug Regulation Reform. Greenberg DS N Engl J Med; 1978 Apr; 298(17):979-80. PubMed ID: 642986 [No Abstract] [Full Text] [Related]
12. Federal regulation: philosophy and practice. Christensen CN Ann Intern Med; 1978 Nov; 89(5 Pt 2 Suppl):835-7. PubMed ID: 363003 [TBL] [Abstract][Full Text] [Related]
13. A few thoughts on the development and regulation of neuropeptides. Gueriguian JL; Chiu YY NIDA Res Monogr; 1986; 70():405-14. PubMed ID: 3093883 [No Abstract] [Full Text] [Related]
14. The drug regulatory system of the United States Food and Drug Administration: a defense of current requirements for safety and efficacy. Simmons HE Int J Health Serv; 1974; 4(1):95-107. PubMed ID: 4829901 [No Abstract] [Full Text] [Related]
15. Drug innovation--what's slowing it down? Steward F; Wibberley G Nature; 1980 Mar; 284(5752):118-20. PubMed ID: 7360238 [No Abstract] [Full Text] [Related]
16. A consideration of the guidelines for investigating potential new drugs in humans in the United Kingdom. McGillion FB Methods Find Exp Clin Pharmacol; 1979 Apr; 1(1):45-50. PubMed ID: 552581 [No Abstract] [Full Text] [Related]
17. [The development of new drugs]. van der Kuy A Tijdschr Ziekenverpl; 1987 Oct; 41(21):676-8. PubMed ID: 3321557 [No Abstract] [Full Text] [Related]
18. Requirements to be fulfilled before instituting clinical trials on new drugs. Griffin JP Proc R Soc Med; 1974 Jun; 67(7):581-4. PubMed ID: 4605052 [No Abstract] [Full Text] [Related]
20. [Development of new drugs--the United States regulatory perspective, 1998]. Averbuch M; Levo Y Harefuah; 1998 Dec; 135(12):638-40. PubMed ID: 10911502 [No Abstract] [Full Text] [Related] [Next] [New Search]